Edging Toward Interchangeability in Biosimilars

An impressive performance by Sandoz at the July 13 Arthritis Advisory Committee on its etanercept biosimilar application suggests progress on the learning curve towards interchangeable applications.

More from US FDA Performance Tracker

More from Regulatory Trackers